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Pediatric brain tumorPurpose: We assessed outcomes after proton therapy (PT) for central nervous system germinomas or
non-germinomatous germ cell tumors (NGGCTs) in children.
Patients and methods: We identified children with germ cell tumors of the central nervous system who
received proton therapy in 2006–2009 and extracted information on tumor response, treatment failures,
and toxicity.
Results: Of the 20 identified patients (median age 12 years [range 3–16]), 9 had germinoma and 11
NGGCTs; 19 patients received three-dimensional conformal PT and 1 scanning-beam PT. Fourteen
patients had craniospinal irradiation (CSI), 4 had ventricular irradiation that excluded the 4th ventricle,
and 2 had whole-ventricle irradiation. All received involved-field boosts. At a median follow-up interval
of 5.6 years (range, 0.3–8.2 years), 1 patient with germinoma had an out-of-field failure in the 4th
ventricle and 2 with NGGCT died from disease progression after CSI. Rates of local control,
progression-free survival, and overall survival at 5 years were 89%, 89%, and 100% for patients with
germinoma; corresponding rates for NGGCTs were 82%, 82%, and 82%. The most common late toxicity
(9 patients [45%]) was endocrinopathy.
Conclusions: PT for CNS germ cell tumors is associated with acceptable disease control rates and toxicity
profiles.
 2016 The Author(s). Published by Elsevier Ireland Ltd on behalf of European Society for Radiotherapy
and Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Central nervous system (CNS) germ cell tumors (GCTs) include
two general types—germinomatous and nongerminomatous germ
cell tumors (NGGCTs). Although treatment has evolved for these
tumors over the past 3 decades, significant controversy remains.
Radiation therapy, whether photons or protons, is a key compo-
nent of treatment for either tumor type. Historically, germinomas
were treated with craniospinal irradiation (CSI); however, concern
for late effects has resulted in CSI being gradually replaced withwhole-ventricular radiation therapy (WVRT). The addition of
chemotherapy may allow further reductions in radiation field size
and dose [1,2]. Given the relatively unfavorable treatment out-
comes for NGGCTs, irradiation of the craniospinal axis is consid-
ered standard by many practitioners. However, new studies are
exploring more limited radiation fields for this type of tumor as
well [3].
Relative to photon-based radiation, particle therapy such as
proton beam therapy (PBT) can improve sparing of normal tissues
[4–6]. Dosimetric comparisons suggest that PBT should reduce
adverse effects for both germinomas and NGGCTs. However,
clinical experience with PBT for such tumors is limited. We sought
to assess tumor response, treatment failures, and toxicity among
children treated for CNS GCTs at The University of Texas MD
Anderson Cancer Center Proton Therapy Center (Houston, TX).proton
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Patient eligibility
Inclusion criteria were (1) a diagnosis of isolated CNS GCT based
on imaging findings, tumor markers, or histologic confirmation; (2)
age 618 years at time of PBT; and (3) receipt of definitive PBT at
the Proton Therapy Center from 2006 through 2009. All patients
were enrolled in a prospective study of proton therapy for pediatric
malignancies approved by the institutional review board. Of the 24
patients initially identified, 4 were excluded who were treated for
recurrent disease after previous photon therapy at other facilities.
The remaining 20 patients comprise the subject of this report.
Tumor classification and staging
CNS GCTs were classified according to the World Health Organi-
zation system [7,8]. Briefly, elevated levels of tumor markers in
serum or cerebrospinal fluid (CSF; alpha-fetoprotein [AFP] level
>10 ng/dL or institutional norm, or beta-human chorionic gonado-
tropin [b-HCG] level >100 mIU/mL) indicated NGGCTs. Extent of
disease was evaluated with brain and spine magnetic resonance
imaging [MRI] and CSF cytology. When more than 1 lesion, only
the diameter of the single largest primary lesion was recorded as
the baseline target lesion size. Primary lesion location was
recorded as pineal, suprasellar, bifocal, or disseminated. Dissemi-
nated disease was defined by imaging or surgical evaluation
(or both) as the presence of: more than 1 intracranial tumor focus
(excluding bifocal disease alone); leptomeningeal spread; spinal
metastases; or tumor cells in the CSF. Surgical interventions were
assessed by reviewing operative and radiology reports and catego-
rized as gross total resection (GTR; complete excision without
residual disease); subtotal resection (STR; residual disease evident
after resection attempt); or biopsy/shunt placement (resection not
attempted).
PBT treatment planning
Treatment plans were based on computed tomography (CT)
simulation with subsequent registration to volumetric MRI scans
to facilitate target volume delineation. Two patients received
WVRT to the entire ventricular system (right and left lateral, third,
and fourth ventricles, with or without prepontine cistern); 4
received WVRT excluding the fourth ventricle (WVRT [minus]
4th); and 14 patients received CSI encompassing the entire
cranium, treated by right posterior oblique and left posterior
oblique beams, and multiple spinal fields defined by posterior–
anterior beams [9]. Proton beam energies ranged from 160 MeV
to 200 MeV. CSI field junctions were shifted to minimize the risk
of potential overlap. All patients received sequential involved-
field boosts. Gross tumor volume (GTV) was defined as the tumor
bed and residual disease, contoured from the pre-chemotherapy
images with adjustment for shifts after surgery or chemotherapy.
A 0.5–1.0-cm margin for microscopic disease was added, as deter-
mined by the treating physician or per protocol, to form the clinical
tumor volume (CTV), with adjustment for anatomic boundaries.
The total prescribed dose was in Gy(RBE), using a relative biologic
effectiveness (RBE) value of 1.1 [10].
Diagnosis and response to treatment
Date of diagnosis was defined as the date of definitive biopsy or,
if no biopsy performed, the date of the first diagnostic MRI and
tumor marker measurement. Follow-up interval was calculated
from date of PBT completion until last known contact. MeasurablePlease cite this article in press as: Greenfield BJ et al. Outcomes for pediatric p
therapy. Clin Transl Radiat Oncol (2016), http://dx.doi.org/10.1016/j.ctro.2016target lesions (P10 mm) at baseline and their subsequent
response to treatment were assessed with the Response Evaluation
Criteria in Solid Tumors (RECIST) guidelines, version 1.1 [11].
Toxicity
Information on tumor- and treatment-related morbidity was
extracted from multidisciplinary clinical evaluations, laboratory
values, and imaging. Treatment-induced toxicity was evaluated
prospectively with the Common Toxicity Criteria for Adverse
Events, version 4.0. Acute toxicity was that appearing <90 days
from the initiation of treatment; P90 days was considered late.
Endocrinopathies were defined as deficiencies confirmed by labo-
ratory screening and requiring supplementary medication. Panhy-
popituitarism was diagnosed by the primary clinician as a
deficiency of >3 anterior pituitary hormones. Visual field and visual
acuity deficits were recorded if physical or ophthalmologic exams
showed declines from baseline. Vascular toxicity was reported if
symptoms correlated with vasculopathy on cranial imaging.
Hypothalamic dysfunction was diagnosed by the primary clinician
on the basis of several related comorbidities, such as thermoregu-
lation dysfunction, behavior disorders, emotional lability, hyper-
phagia, morbid obesity, sleep disturbances, autonomic instability,
and metabolic syndrome.
Statistical analysis
Patient, tumor, and treatment characteristics were evaluated
with descriptive statistics. Categorical data were analyzed for non-
random associations with Pearson’s v2 test (Fisher’s exact test used
if <5 values per cell). Wilcoxon’s rank-sum tests were used to com-
pare outcomes between two independent groups with continuous
data. Overall survival (OS) was calculated from date of diagnosis
until date of last known contact or death. Progression-free survival
(PFS) was calculated from date of completion of PBT until date of
tumor progression or recurrence, last known contact, or death.
The Kaplan–Meier method was used to calculate OS and PFS times.
Two-sided P values of <0.05 were considered statistically signifi-
cant. Analyses were performed with JMP software (version
10.0.2; SAS Institute Inc.).
Results
Patient and treatment characteristics
Twenty patients met criteria for this analysis; patient, disease,
and treatment characteristics are summarized in Table 1. Median
age at initial diagnosis was 12.0 years (range, 3.4–16.1 years).
Seven patients (35%) initially had evidence of disseminated disease
(4 with gross intracranial seeding, 4 with positive CSF cytologic
findings, and 1 with infiltrating intra-axial extension >1 cm beyond
tumor). No patients had initial gross seeding of the spinal canal.
Seventeen patients (85%) had surgical intervention at diagnosis.
Of these, 3 had initial STR to relieve compressive symptoms before
definitive chemoradiotherapy; 1 with a solitary pineal mixed
NGGCT (patient 10) developed asymptomatic cyst growth during
chemotherapy and underwent cyst decompression to reduce the
boost volume before PBT was begun; and 1 had growing teratoma
syndrome (patient 18), once during chemotherapy and once during
radiation therapy, both requiring emergent debulking procedures.
Second emergent surgery was a GTR followed by completion of
the planned chemoradiotherapy regimen, with no evidence of
recurrence at 5.2 years follow-up.
Four patients with germinoma received definitive PBT, and the
other 5 received induction chemotherapy followed by PBT. Two
patients (10%) were 65 years old at the time of PBT. PBT wasatients with central nervous system germ cell tumors treated with proton
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Table 1
Patient, disease, and treatment characteristics.
Characteristics Value or no. of patients (%)
All patients [n = 20] Patients with germinoma [n = 9] Patients with NGGCT [n = 11] P Value
Follow-up, time, months
Median (range) 58.2 (3.7–89.9) 62.0 (49.9–89.9) 55.3 (3.7–77.6) 0.184
Age at RT, years
Median (range) 12.5 (4.0–16.4) 12.5 (7.9–16.4) 12.4 (4.0–14.1) 0.648
Tumor size, cm
Median (range) 3.0 (0.9–6.0) 2.9 (0.9–5.5) 3.2 (2.0–6.0) 0.323
Sex
Male 11 (55) 5 (56) 6 (55) 1.000
Female 9 (45) 4 (44) 5 (45)
Race/ethnicity
Asian 2 (10) 0 (0) 2 (18) 0.303
African American 2 (10) 2 (22) 0 (0)
Hispanic 4 (20) 1 (11) 3 (27)
Caucasian 12 (60) 6 (67) 6 (55)
Tumor location
Suprasellar 5 (25) 2 (22) 3 (27) 0.240
Pineal 8 (40) 3 (33) 5 (45)
Bifocal 1 (5) 1 (11) 0 (0)
Disseminated 6 (30) 3 (33) 3 (27)
Presenting symptoms
Hydrocephalus 13 (65) 5 (56) 8 (73) 0.642
Visual symptoms 16 (80) 8 (89) 8 (73) 0.591
Endocrinopathy 10 (50) 5 (56) 5 (45) 1.000
Initial surgical intervention
None 3 (15) 0 (0) 3 (27) 0.248
Biopsy and/or shunt 14 (70) 8 (89) 6 (55)
STR 2 (10) 1 (11) 1 (9)
GTR 1 (5) 0 (0) 1 (9)
Induction chemotherapy
Yes 16 (80) 5 (56) 11 (100) 0.026
No 4 (20) 4 (44) 0 (0)
Primary radiation field
WVRT ± 4th Ventricle 6 (30) 5 (56) 1 (9) 0.050
CSI 14 (70) 4 (44) 10 (91)
Radiation dose, Gy(RBE)
Median (range) 52.2 (30.0–54.0) 45.0 (30.0–45.0) 54.0 (54.0–54.0) <0.001
Abbreviations: NGGCT, nongerminomatous germ cell tumor; RT, radiation therapy; STR, subtotal resection; WVRT (4th), whole-ventricular radiotherapy (excluding the
fourth ventricle); CSI, craniospinal irradiation.
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scanning-beam techniques to 1 patient (patient 9). The dose per
fraction was 1.5 Gy(RBE) or 1.8 Gy(RBE).
Outcomes
Median follow-up time for entire cohort was 5.6 years (range,
0.3–8.2 years) with a 5-year local control, PFS, and OS rates of
85%, 85%, and 90%. Germinoma patients had a median follow-up
time of 5.5 years (range, 4.2–8.2 years) with 5-year PFS and OS
rates of 89% and 100%. NGGCTs patients had a median follow-up
time of 5.8 years (range, 0.3–7.9 years; 2 patients died within
6 months follow-up), with 5-year PFS and OS rates of 82% and
82%. Two patients were lost to follow-up at 5.1 years and 4.3 years;
after their care was transferred to other facilities. Details of treat-
ment characteristics and outcomes are given in Table 2.
At last follow-up, no evidence of active disease was present in
all 9 germinoma patients and in 8 (73%) of the NGGCT patients.
All patients without tumor progression had normalization of
tumor markers after chemotherapy, including 2 patients with
stable radiographic disease.
Four patients had disease progression, 3 within 13 months of
PBT; 2 of these events directly contributed to the 2 deaths reported
(patients 15 and 19). The first failure (patient 8) had localizedPlease cite this article in press as: Greenfield BJ et al. Outcomes for pediatric p
therapy. Clin Transl Radiat Oncol (2016), http://dx.doi.org/10.1016/j.ctro.2016.suprasellar germinoma (pure germinoma histology with CSF
b-HCG [77 mIU/mL]), initially treated with chemotherapy followed
byWVRT excluding the 4th ventricle. Disease progression occurred
12.7 months after PBT, with a ‘‘drop” metastasis in the 4th ventri-
cle (at the inferior end of previously treated 30 Gy isodose line).
Salvage therapy was 36 Gy CSI, given with intensity modulated
photon-based RT, which resulted in remission throughout remain-
ing 4.9 years follow-up.
The second failure (patient 15) had a localized pineal NGGCT
(initial serum AFP >3000 ng/dL) with refractory disease (tumor
growth) after initial chemotherapy and CSI. Salvage treatment
included GTR followed by high-dose chemotherapy with autolo-
gous stem-cell transplant then 13 cis-retinoic acids. Despite stable
minimal residual disease throughout follow-up, biochemical fail-
ure (increased AFP) occurred at 2.1 months follow-up. Patient died
at 3.7 months follow-up.
The third failure (patient 19) had a localized pineal NGGCT (ini-
tial serum AFP 551 ng/dL) with no residual tumor evident on imag-
ing after initial chemotherapy and CSI. At 1-month follow-up, MRI
revealed several new brain and spine lesions. High-dose
chemotherapy was begun, but a severe infection developed before
the planned transplant. Patient died at 6 months follow-up.
The forth failure (patient 10) had a pineal NGGCT (pure
germinoma on biopsy, but with elevated serum and CSF AFPatients with central nervous system germ cell tumors treated with proton
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Table 2
Treatment characteristics and outcomes for 20 patients with central nervous system germ cell tumors.
Presentation Surgery Chemotherapy Radiation therapy Outcomes
Pt
#
Sex Age
(yrs)
Tumor Initial
resection
Type
(cycles)
Response Initial
volume
Dose [Gy(RBE)] Response (3
mo f/u)
Progression
(Salvage)
At last
follow-up
Type Location Initial Boost Total
1 F 11 Germinoma Suprasellar Biopsy — — WVRT4th 25.2 16.2 41.4 CR No NED
2 M 13 Germinoma Pineal Biopsy* — — WVRT4th 25.2 19.8 45.0 CR No NED
3 M 16 Germinoma Pineal Biopsy* CE(2)
+ PC(2)
PR WVRT4th 21.6 18.0 39.6 CR No NED
4 M 12 Germinoma DD Biopsy CE(2)
+ PC(2)
PR CSI 21.0 9.0 30.0 CR No NED
5 F 8 Germinoma DD STR CE(1)** PR CSI 21.6 18.0 39.6 CR No NED
6 M 15 Germinoma Bifocal Biopsy — — CSI 21.6 23.4 45.0 CR No NED
7 F 16 Germinoma DD Biopsy CE(2) CR CSI 21.6 23.4 45.0 NED No NED
8 F 8 Germinoma Suprasellar Biopsy* ICE(6) PR WVRT4th 23.4 21.6 45.0 CR Yes (IMRT) NED
9 M 9 Germinoma Pineal Biopsy — — WVRTy 23.4 21.6 45.0 CR No NED
10 M 12 NGGCT Pineal Biopsy* ICE (6) SD CSI 36.0 18.0 54.0 PR Yes (chemo) Alive w/
disease
11 M 12 NGGCT Pineal Shunt ICE (6) SD CSI 30.6 23.4 54.0 SD No NED
12 F 13 NGGCT Suprasellar Shunt* ICE (6) CR CSI 30.6 23.4 54.0 NED No NED
13 M 14 NGGCT DD Biopsy ICE (6) PR CSI 36.0 18.0 54.0 CR No NED
14 M 14 NGGCT Pineal Shunt ICE (6) PD CSI 30.6 23.4 54.0 SD No NED
15 M 12 NGGCT Pineal Biopsy* ICE (3)** SD CSI 36.0 18.0 54.0 SD Yes§ Deceased
16 F 14 NGGCT DD — ICE (6) PR CSI 30.6 23.4 54.0 CR No NED
17 F 4 NGGCT Suprasellar STR PEI
(4)***
CR WVRT 21.6 32.4 54.0 NED No NED
18 F 5 NGGCT Suprasellar STR/GTR* ICE (6) NED CSI 36.0 14.4 50.4 NED No NED
19 M 13 NGGCT Pineal — ICE (6) CR CSI 30.6 23.4 54.0 NED Yes (none) Deceased
20 F 9 NGGCT DD — ICE (6) PR CSI 36.0 18.0 54.0 CR No NED
Abbreviations: NGGCT, nongerminomatous germ cell tumor; DD, disseminated disease; STR, subtotal resection; GTR, gross total resection; CE, carboplatin, etoposide; PC,
cisplatin, cyclophosphamide; ICE, ifosfamide, carboplatin, etoposide; PEI, cisplatin, etoposide, ifosfamide; PD, progressive disease; SD, stable disease; PR, partial response; CR,
complete response; NED, no evidence of active disease; WVRT4th, whole-ventricular radiotherapy (excluding the fourth ventricle); CSI, craniospinal irradiation; IMRT,
intensity-modulated (photon) radiation therapy.
* Additional surgical interventions before radiation therapy included shunt placement, additional biopsy, or both.
** Chemotherapy-related toxicity prevented completion of additional planned cycles.
*** Last two of four cycles consisted of high-dose PEI followed by autologous stem cell rescue.
y Patient received intensity-modulated proton therapy (IMPT); all others received 3D-conformal proton therapy.
 Cyst growth requiring shunt placement for symptomatic hydrocephalus at 5.5 years follow-up; no change in solid tumor and tumor markers remained normal throughout
follow-up.
§ Refractory to chemoradiotherapy; salvaged with gross total resection, high dose chemotherapy (temozolomide, thiotepa, carboplatin), and autologous stem cell rescue
followed by 13 cis-retinoic acid.
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recurrence with abnormal serum and CSF AFP levels occurred at
7.6 years follow-up. At time of this report, patient was receiving
additional chemotherapy, with planned consolidative myeloabla-
tive chemotherapy and autologous stem-cell transplant.
Toxicity analyses
Acute-onset radiotherapy-related toxicity requiring medical
intervention included brain edema (n = 4) and somnolence
syndrome (n = 1), all of which resolved with steroids. One patient
treated with CSI reported odynophagia during PBT that required
pain medication. No grade 3 or 4 acute toxicities were recorded.
At initial presentation, 5 patients had hypothalamic dysfunc-
tion, with panhypopituitarism and primary suprasellar tumors that
extensively involved the hypothalamus. No other patients devel-
oped documented hypothalamic dysfunction throughout treat-
ment or follow-up.
At initial presentation, only patients with suprasellar tumor
involvement (n = 10) hadP1 endocrinopathies (P < 0.001), includ-
ing hypothyroidism (n = 10), hypogonadism (n = 7), diabetes insipi-
dus (n = 8), adrenal insufficiency (n = 6), and growth hormone (GH)
deficiency (n = 5). PBT dose–volume review revealed a median
hypothalamic-pituitary mean dose of 43.8 Gy(RBE) (range, 18.0–
53.7 Gy(RBE)) and a median thyroid mean dose of 0.0 Gy (range,
0.0–0.2 Gy).
All 10 patients with panhypopituitarism at last follow-up also
had panhypopituitarism before PBT; 7 at initial presentation andPlease cite this article in press as: Greenfield BJ et al. Outcomes for pediatric p
therapy. Clin Transl Radiat Oncol (2016), http://dx.doi.org/10.1016/j.ctro.20163 shortly after the initial surgical intervention. All 11 patients with
diabetes insipidus at last follow-up were diagnosed prior to PBT.
Nine patients were diagnosed with new-onset post-treatment
endocrinopathies; 7 with GH deficiency alone, 1 with GH defi-
ciency and hypothyroidism (hypothalamic-pituitary mean dose
of 38 Gy), and 1 with primary/secondary hypogonadism attributa-
ble to both chemotherapy and PBT (hypothalamic-pituitary mean
dose of 48 Gy). GH deficiency at last follow-up was associated only
with suprasellar tumor involvement (P = 0.004); no association
was found with total dose (P = 0.685) or hypothalamic-pituitary
mean dose (P = 0.808).
Sixteen patients (80%) had documented visual symptoms or
signs at initial presentation, including 10 with dorsal midbrain
syndrome, 5 with visual field or visual acuity deficits (all had pri-
mary suprasellar tumor involvement of the optic apparatus), and
7 with diplopia secondary to cranial nerve VI palsy. Only 1 patient
experienced improvement of visual field and acuity deficits which
occurred after initial STR.
Two patients developed new-onset visual symptoms with acu-
ity deficits within 1–3 years after PBT; both presented with pineal
tumors, dorsal midbrain syndrome, diplopia secondary to cranial
nerve VI palsy, and hydrocephalus requiring shunt placement. Both
patients initially had 20/20 visual acuity bilaterally with subse-
quent worsening in visual acuity (20/70) during follow-up. One
patient developed bilateral optic neuritis, most likely secondary
to a yet-undefined autoimmune disease, and the other developed
unilateral optic atrophy. Neither patient had additional surgery,
chemotherapy, or radiation after PBT. Treatment plan review ofatients with central nervous system germ cell tumors treated with proton
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<39 Gy, and optic chiasm maximum doses of 31.4 Gy and 51.2 Gy
(corresponding mean doses 26.8 Gy and 40.6 Gy). For comparison,
the 13 patients without visual deficits during the course of disease
had a median optic chiasmmaximum dose of 51.2 Gy (range, 22.1–
54.2 Gy) and a median optic nerve maximum dose of 37.5 Gy
(range, 7.5–53.8 Gy).
Although formal neurocognitive testing was not done consis-
tently, 14 patients were reported to be doing well in school or to
have active careers at last follow-up. One patient was diagnosed
with a late-onset seizure disorder at 4 years follow-up, but this
patient had also experienced multiple falls with head injuries,
attributed to gait ataxia caused by chemotherapy-induced
neuropathy.
Patient 18, who had a large (5.2-cm) 3rd ventricle suprasellar
NGGCT (mature and immature teratoma involving bilateral thala-
mic and basal ganglia) was diagnosed with Moyamoya disease
after the sudden appearance of choreoathetoid movement of the
right arm at 3 years after multiple surgical interventions (STR,
GTR, and two shunts) followed by chemoradiotherapy (at 5 years
of age). This patient’s choreoathetoid movement resolved without
intervention, and the vasculopathy has been stable without requir-
ing intervention other than prophylactic daily aspirin.Discussion
Our findings demonstrate that PBT can provide favorable
clinical outcomes for germinomas and NGGCTs, with favorable late
toxicity profiles. For germinomas, our 5-year OS rate of 100% and
PFS rate of 89% were consistent with recent photon-based studies,
with reported 5-year OS rates of >90% and PFS 90% [12–15].
Corresponding rates for NGGCT (OS 82% and PFS 82%) were also
consistent with recent photon-based studies, with 5-year OS rates
of 70–93% and PFS 40–84% [3,16–18]. These results suggest that
the high dose conformality profile of PBT does not compromise
long-term local control or OS relative to photon-based RT to similar
treatment volumes. Our results are similar to those of a
22-patient experience at Massachusetts General Hospital [5] in
which OS and PFS rates were 100% and 95% at a median follow-
up time of 28 months.
Despite efforts to minimize the use of RT, several groups have
shown that chemotherapy alone has poorer local control outcomes
[21,22] and that smaller RT target volumes are associated with
marginal failures in many subsets of patients [12,15–21,23,24]. In
our study, 4 germinoma patients received PBT to the whole-
ventricle system excluding the 4th ventricle; of these, 1 patient
with an initial mild elevation in b-HCG (77 mIU/mL) had a recur-
rence within the 4th ventricle at 1.1 years follow-up. These results
support the routine use of comprehensive ventricular irradiation.
The dose distribution of proton therapy has been shown in
many dosimetric comparisons to be superior to that obtained with
conformal photon-based RT techniques [4–6]. Macdonald et al.
recently demonstrated this benefit for pediatric patients with
CNS GCT, reporting sparing of the brain and temporal lobes with
PBT in comparison to photon-based therapy [5]. Although patients
who receive PBT radiation therapy likely benefit from reductions in
radiation dose and volume, currently no study has comprehen-
sively and prospectively described neurocognitive outcomes for
patients who receive proton therapy for GCTs [19,25,26]. However,
initial studies do suggest the potential for improved quality of life
following proton therapy in comparison to photon treatment [27].
Hypothalamic dysfunction, endocrinopathy and visual deficits
in children with CNS GCTs are commonly linked to initial tumor
involvement, surgical manipulation, or both [19,20]. Indeed, all
hypothalamic dysfunction and most endocrinopathies in our studyPlease cite this article in press as: Greenfield BJ et al. Outcomes for pediatric p
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most common RT-related hormone deficiency, but can also result
from surgical manipulation, location of intracranial tumors, and
the hypothalamic-pituitary RT dose [20,28–30]. In our study, GH
deficiency was the most common new-onset endocrinopathy after
PBT, and most patients had suprasellar tumor involvement and
therefore received the total planned RT dose to the
hypothalamic-pituitary axis. GH deficiency has been reported after
doses as low as 18 Gy; therefore, GH deficiency was not
unexpected.
A quarter of patients in the current study presented with visual
field or acuity deficits at initial presentation, which were related to
suprasellar tumor involvement of the optic apparatus. For photon
therapy, few radiation-induced optic neuropathies have been
found at treatment doses of 654 Gy in 1.8-Gy fractions [31]. In
our study, two patients developed new-onset visual deficits within
1–3 years of completing PBT. These patients had no additional
trauma or therapies to explain the visual deficits. However, one
of the patients was diagnosed with an unidentified autoimmune
disorder that may have accounted for several episodes of bilateral
neuroretinitis. Neither of these patients had received >52 Gy to the
optic apparatus according to their treatment plans, nor did any
beams have distal edges placed within the chiasm or nerve. Fur-
ther, several other patients with similar or greater doses to the
optic apparatus did not have any visual deficits throughout the
entire course of disease or follow-up.
One patient who was 5 years old at the time of PBT was later
diagnosed with Moyamoya syndrome 3 years after PBT. A rare
complication of childhood intracranial cancers, Moyamoya syn-
drome has been linked with RT, especially when children are
younger than 5 at time of treatment [32]. Young children are
thought to be more susceptible to surgical or radiation injury
because their vasculature is in its greatest phase of growth [33].
No secondary malignancies were found in this study, although
further follow-up would be needed to elicit long-term risks relative
to those from to photon-based RT [18,33,34].
This study did have limitations common to single-institution
reports of rare pediatric diseases, including small sample size.
Treatment factors including chemotherapy use, target volume
delineation and dose prescription also varied considerably. Lastly,
objective standardized neurocognitive measures at scheduled
intervals would be needed to further clarify the absolute benefit
of PBT with regard to sparing the normal brain tissue and, corre-
spondingly, improving neurocognitive outcomes.
Conclusion
Using PBT to treat pediatric GCTs resulted in acceptable long-
term local control, OS, and toxicity outcomes compared with
photon-based RT.
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